T. Rowe Price Associates
KURA icon

T. Rowe Price Associates’s Kura Oncology KURA Stock Holding History

T. Rowe Price Associates’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$768K Buy
69,962
+11,868
+20% +$112K ﹤0.01% 2436
2026
Q1 		$473K Buy
58,094
+12,367
+27% +$106K ﹤0.01% 2485
2025
Q4 		$476K Buy
45,727
+3,768
+9% +$39.5K ﹤0.01% 2419
2025
Q3 		$372K Buy
41,959
+2,386
+6% +$17K ﹤0.01% 2501
2025
Q2 		$229K Buy
39,573
+7,855
+25% +$48.1K ﹤0.01% 2657
2025
Q1 		$210K Buy
31,718
+3,648
+13% +$28.4K ﹤0.01% 2611
2024
Q4 		$245K Buy
28,070
+4,344
+18% +$62.5K ﹤0.01% 2603
2024
Q3 		$464K Buy
23,726
+672
+3% +$13.6K ﹤0.01% 2280
2024
Q2 		$475K Buy
23,054
+2,906
+14% +$59.7K ﹤0.01% 2207
2024
Q1 		$430K Buy
20,148
+2,940
+17% +$57.2K ﹤0.01% 2271
2023
Q4 		$248K Sell
17,208
-17,659
-51% -$174K ﹤0.01% 2455
2023
Q3 		$318K Buy
34,867
+10,499
+43% +$107K ﹤0.01% 2310
2023
Q2 		$258K Buy
24,368
+608
+3% +$7.19K ﹤0.01% 2435
2023
Q1 		$291K Buy
23,760
+975
+4% +$12.2K ﹤0.01% 2356
2022
Q4 		$283K Sell
22,785
-3,963
-15% -$57.6K ﹤0.01% 2395
2022
Q3 		$366K Sell
26,748
-11,048
-29% -$170K ﹤0.01% 2284
2022
Q2 		$693K Buy
37,796
+423
+1% +$6.08K ﹤0.01% 2068
2022
Q1 		$601K Buy
37,373
+15,296
+69% +$221K ﹤0.01% 2258
2021
Q4 		$309K Sell
22,077
-17,278
-44% -$280K ﹤0.01% 2588
2021
Q3 		$737K Buy
39,355
+6,336
+19% +$119K ﹤0.01% 2195
2021
Q2 		$688K Buy
33,019
+1,273
+4% +$31.6K ﹤0.01% 2233
2021
Q1 		$897K Buy
31,746
+7,924
+33% +$251K ﹤0.01% 2110
2020
Q4 		$778K Buy
23,822
+2,926
+14% +$103K ﹤0.01% 2048
2020
Q3 		$640K Buy
+20,896
New +$461K ﹤0.01% 1990

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

T. Rowe Price Associates's KURA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Kura Oncology (KURA) stake by 20% in Q2 2026, buying an estimated $112K and bringing the position to 69,962 shares worth $768K. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

T. Rowe Price Associates first reported a position in KURA in Q3 2020 and has held it in 24 quarters since. The position peaked at $897K in Q1 2021. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • T. Rowe Price Associates held 69,962 shares of Kura Oncology worth $768K as of Q2 2026.
  • T. Rowe Price Associates bought 11,868 Kura Oncology shares in Q2 2026, an estimated $112K.
  • Kura Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2436 holding.
  • T. Rowe Price Associates first reported a position in Kura Oncology in Q3 2020 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Kura Oncology position peaked at $897K in Q1 2021.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.